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Abstract 
 
Background: There has been an appreciable increase in the number of people in Africa with 
metabolic syndrome and Type 2 diabetes (T2DM) in recent years as a result of a number of factors. 
Factors include lifestyle changes, urbanisation, and the growing consumption of process foods 
coupled with increasing levels of obesity. Currently there are 14.2 million adults in sub-Saharan Africa 
(SSA) with diabetes, mainly Type 2 diabetes (T2DM) (95%), estimated to grow to 34.2 million people 
by 2040 unless controlled. This has a considerable impact on morbidity, mortality and costs in the 
region. There are a number of issues to address to reduce the impact of T2DM including improving 
detection rates and current access to services alongside addressing issues of adherence to 
prescribed medicines. There are also high rates of co-morbidities with infectious diseases such as 
HIV and TB in patients with T2DM in SSA that requires attention. Objective: Document ongoing 
activities across Africa to improve the care of patients with T2DM especially around issues of 
identification, access, and adherence to changing lifestyles and prescribed medicines. In addition, 
suggest potential ways forward to improve the care of patients with T2DM based on ongoing activities 
and experiences including addressing key issues associated with co-morbidities with infectious 
diseases. Our Approach: Contextualise the findings from a wide range of publications including 
internet based publications of national approaches coupled with input from senior level government, 
academic and other professionals from across Africa to provide future guidance. Ongoing activities: 
A number of African countries are actively instigating programmes to improve the care of patients with 
T2DM starting with improved diagnosis. This recognises the growing burden of NCDs across Africa, 
which has been neglected in the past. Planned activities include programmes to improve detection 
rates and address key issues with diet and lifestyle changes, alongside improving monitoring of care 
and activities to improve adherence to prescribed medicines as well as address potential complexities 
involving diabetes patients with infectious disease co-morbidities. It is too early to fully assess the 
impact of such activities, Conclusion: There are a number of ongoing activities across Africa to 
improve the management of patients with diabetes including co-morbidities. However, more needs to 
be done considering the high and growing burden of T2DM in Africa. Ongoing research will help 
further benefit resource allocation and subsequent care. 
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Introduction 
 
The number of overweight and obese people is rising across Africa as a result of changes in lifestyles 
including reduced physical activity, more sedentary lifestyles, changing dietary habits including easy 
access to inexpensive process foods, cultural habits, and increasing urbanisation (1-12). Such 
changes are leading to an increase in the number of patients with metabolic syndrome and Type 2 
diabetes (T2DM) across the continent (10, 13-15). Studies in South Africa suggest over 50% of the 
adult population (18 years and above) are overweight or obese and rising (1), and in Nigeria 62% and 
49% respectively of adults are overweight or obese (16). Kenyan women were also reported to be 
significantly more likely to have abdominal obesity compared to men (50.2% vs. 12.1%) (17). 
However, diabetes in sub-Saharan Africa is also present in patients with low to normal body mass 
indices (BMIs), which may reflect genetic diversities compared with populations in other continents 
(18). Overall, diabetes mellitus is a growing problem across Africa with an estimated 15.9 million 
affected including 14.2 million in sub-Saharan Africa (SSA) (18-21). Numbers are likely to grow to 
34.2 million people in SSA by 2040 and up to 41.6 million across Africa by 2045, principally T2DM 
(20-23).  
 
As mentioned, rapid urbanization in Africa is one of the principal risk factors for increasing rates of 
T2DM across the continent. SSA is often regarded as the world's fastest urbanizing region, with the 
global share of African urban residents projected to grow from 11.3% in 2010 to 20% in 2050 (24). 
The city of Johannesburg in South Africa has been a part of a world-wide initiative called ‘Cities 
Changing for Diabetes’, the purpose of which is to improve the management of patients with diabetes 
in urban areas using the principles of halves, i.e. approximately 50% of people with diabetes are 
diagnosed, of whom 50% receive care, of whom 50% achieve treatment target (recommended 
glucose levels), of whom approximately 50% would subsequently lead a life free from diabetes related 
complications equating to 6% of those with diabetes (25). 
  
Activities are just starting across SSA to improve the care of patients with T2DM (Table 1). Typically 
though, the awareness of diabetes among patients remains a major challenge in SSA with only a 
minority of patients currently aware of their diabetic status and being actively treated, with only a small 
percentage being diagnosed pre-diabetes (11, 26). This needs to be urgently addressed given the 
morbidity, mortality and costs associated with diabetes (27-35). 80% of early deaths due to non-
communicable diseases (NCDs) including diabetes and cardiovascular diseases (CVD) currently 
occur in lower and middle income countries (LMICs), with the morbidity and mortality of diabetes and 
other NCDs such as CVD likely to be greater than communicable disease by 2025  (36-38). Overall, 
SSA currently has the highest rate of morbidity and mortality associated with diabetes world-wide (20, 
21). In South Africa for instance as a result of changes in peoples’ diet and lifestyle, diabetes has 
moved from being the fifth leading underlying cause of death in 2013 to now the second most 
common cause, representing 5.5% of all recorded deaths (39, 40). T2DM also results in a lower 
health status and quality of life (29, 33, 41, 42), with high rates of sight threatening retinopathy among 
diabetic patients in SSA (20, 30, 31, 43, 44) as well as nephropathy (45, 46) and neuropathy (47, 48). 
Overall, populations of African origin appear to have the highest prevalence of microvascular 
complications of diabetes exacerbated by frequent high blood pressure and inappropriate diabetes 
control among the diabetes population along with challenges of access to appropriate care (49, 50).   
 
Prevalence rates of T2DM vary considerably among individual countries in SSA, exacerbated by high 
rates of undiagnosed cases of diabetes (26, 32, 35, 51, 52) (Appendix -1). Overall, it is estimated that 
up to 70% or more of cases of diabetes are currently undiagnosed in SSA (20, 21, 41, 49, 53). This is 
a concern as diabetes and its associated comorbidities increase cardiovascular diseases (CVD), 
which are responsible for approximately 70% of diabetes-related deaths (28, 34, 54, 55). It is hoped 
that ongoing activities across Africa (Table 1) will start to address this especially with mortality rates 
are enhanced by the lack of control of blood pressure, HbA1c and lipid levels, especially low density 
lipoproteins (LDL-C), coupled with inactivity (56-59). Currently, only a minority of patients with 
diabetes in Africa achieve optimal therapeutic targets (26, 60, 61), which is a real concern.  
 
The economic impact of diabetes in SSA is also increasing with growing prevalence rates (53). Atun 
et al recently estimated that in 2015, the overall cost of diabetes in SSA was 1.2% of the gross 
domestic product (GDP), with approximately US$10·81 billion spent on direct medical costs with out-
of-pocket expenditure likely to exceed 50% of overall health expenditure in many of the countries (35). 
In Nigeria, estimates suggest the annual direct costs of diabetes are up to US$1.639 billion per year 
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in view of its population size and current prevalence rates, with the estimated monthly direct medical 
costs for patients with T2DM in Cameroon at US$148 per patient and in Nigeria varying between 
$262.22 to $400.52 per patient (27). Median monthly healthcare expenditure in Kenya in households 
with diabetes was US$100.00 of which US$7.00 was on medicines (62). The effect of NCDs in the 
work place is also of growing concern across countries including Kenya and South Africa (63).  
 
Diagnosis rates need to be improved to achieve the World Health Organisation’s (WHO) 25×25 
Global Action Plan (2013) as well as Sustainable Development Goal (SDG) 3 goals to reduce 
premature deaths due to non-communicable diseases (NCDs) by a third by 2030 (64, 65). Concerns 
with rising rates of T2DM and its impact will persist unless addressed. This includes access to 
diagnostics and essential medicines in the first place (49, 66) along with adequate diagnostic facilities 
(26) given current concerns with diagnosis rates. The WHO in 2015 found that in Africa only 51% of 
the countries had metformin routinely available and only 40% insulin, well below the 80% target (35). 
This is a major concern especially with only metformin along with gliclazide and glibenclamide 
included in the WHO essential medicine list (EML) (67). There have been concerns though with 
hypoglycaemia with sulphonyl ureas (SUs) (68).  However, this applies more to glibenclamide than 
other SUs including glipizide, glimepiride and gliclazide as well as gliclazide MR (69-71). This is 
reflected in the current South African guidelines recommending that glibenclamide should no longer 
be prescribed, with for instance gliclazide MR replacing the more general term SUs (68). Having said 
this in Nigeria, glibenclamide is still on the national EML; however, chlorpropamide is still being 
prescribed by some practitioners (72, 73). There have also been concerns recently with limited 
availability of insulin analogues when needed especially with the increasing availability of lower costs 
biosimilars. However in the first instance, soluble insulin injections as well as intermediate acting 
insulins need to be made routinely available to T2DM patients within public healthcare systems 
across SAA in accordance with the 2019 WHO EML before potentially funding any analogue (67).  
 
The availability of medicines to treat patients with T2DM should improve with ongoing  programmes 
across SSA, including South Africa, to improve access to medicines in patients with chronic diseases 
(74) as well as ongoing programmes to reduce the costs of medicines as a barrier to their use (75).  
However, more remains to be done with continual concerns regarding the availability of metformin 
and insulins across SSA. Efficient procurement of medicines is critical to ensure that patients with 
diabetes within public healthcare systems are able to obtain an uninterrupted supply of their 
medicines (76).  
 
Newer oral medicines for patients with T2DM such as the DPP4 (dipeptidyl peptidase-4) and SGLT2 
(sodium/glucose cotransporter 2) inhibitors have also been proposed (68, 77, 78). However, there are 
major issues with affordability within public healthcare systems struggling to routinely make available 
metformin and basic insulins. In addition, a number of patients with T2DM across Africa are ketosis 
prone and this is difficult to manage if their renal function is not routinely monitored in primary 
healthcare centres (PHCs). However, it is difficult to estimate the true prevalence of patients who are 
ketosis prone in SSA. Ketosis-prone diabetes is an “atypical” form of diabetes particularly prevalent in 
diabetic patients in SSA with characteristics of both Type 1 and Type 2 diabetes (49, 79, 80), 
principally though ketosis-prone T2DM (79) Published figures suggest a prevalence up to 15% of the 
diabetes population in Africa have ketosis-prone diabetes (49, 79, 81); however, this could be an 
under estimate. In addition, there are also concerns with available resources and co-payments within 
public healthcare systems in SSA leading to continued endorsement and listing of appropriate SUs 
and metformin rather than funding newer oral medicines such as the DPP4 and SGLT2 inhibitors, as 
well as addressing any inertia with prescribing insulins rather than again funding newer oral anti-
diabetic medicines (82, 83).  
 
Alongside this, many countries in SSA currently have inadequate facilities to manage both the 
microvascular and macrovascular complications of T2DM(35). This includes addressing sub-optimal 
management of patients with T2DM with currently only a minority of patients in SSA achieving 
glycaemic control (26, 60, 61, 66, 84, 85). Glycaemic control is improved though in specialist centres 
in SSA (61, 83, 86). This reflects the fact that NCDs such as diabetes have been relatively neglected 
over the last decade in SSA in favour of infectious diseases including human immunodeficiency 
viruses (HIV), tuberculosis (TB) and malaria due to their burden (20, 35, 87). However, this is 
beginning to change (Table 1 below).  Diabetic populations of African origin appear to have the 
highest prevalence of microvascular complications exacerbated by frequent high blood pressure and 
inappropriate diabetes control along with challenges with access to appropriate care (49, 50).  
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Treatment of hypertension is a particular concern among the black population. Thiazide diuretics and 
calcium channels blockers rather angiotensin-converting-enzyme inhibitors (ACE inhibitors) are now 
seen as the most effective antihypertensives in the black population (88-90). Consequently, whilst 
ACE inhibitors are indicated for patients with diabetes and proteinuria, they have a lesser effect in 
reducing blood pressure in the black population and their prescribing needs to be carefully managed 
(83, 91). There is also typically low use of statins among diabetic patients in SSA, which again needs 
to be urgently addressed to reduce future CV complications (61, 83, 92).  
 
Overall, a number of key issues have been identified surrounding the management of patients with 
T2DM in SSA that need to be addressed alongside issues of diagnosis and medicine availability. 
These include access to care in the first place, which is typically among public sector PHCs across 
most of SSA (35). Access to physicians and medicines continues to be a challenge especially if this 
involves high patient co-payments and/ or there are long distances and queues to see a healthcare 
professional, both of which have economic and emotional consequences for patients (93-95). The 
prohibitive costs of medicines in some LMICs, which can account for up to 60% or more of total 
healthcare costs, does affect continued medicine use if much of this is out-of-pocket including 
adherence for long term chronic conditions such as T2DM (96-99). For instance in Nigeria, typically 
household savings and family support are needed to fund treatments for patients with T2DM, with a 
mean monthly expenditure of US$356 per patient (100) similar to other studies (27). In addition, for 
patients with diabetes in Nigeria, the costs of medicines can account for over 70% of total direct 
medical costs (101). Greater use of generic medicines could help reduce these costs (102); however, 
there are issues with the quality of generics in Nigeria which needs to be addressed (103). 
 
Patient knowledge regarding diabetes and its management, including self-management, can also be 
poor among patients with T2DM in SSA (40, 104-106). This is exacerbated by low levels of education 
among patients attending PHCs in SSA with CVD including T2DM and hypertension; however, this is 
not universal (40, 94, 107-112). In addition, there are concerns that being overweight and obese is 
still seen as a sign of affluence in a number of African communities, although changing, and 
appreciable weight loss still has the stigma of HIV and acquired immune deficiency syndrome (AIDS) 
associated with it. This is important especially in countries where there are high prevalence rates of 
HIV as well as high rates of patients with both HIV and T2DM as seen for instance in Botswana 
compared with high income countries (113, 114). Treatment, including adherence to agreed 
guidelines for patients with T2DM, and subsequent patient adherence to prescribed medicines, are 
also generally sub-optimal in LMICs including Africa (40, 101, 107, 115-119).  
 
A number of factors appear responsible for poor control of T2DM including the age of patients, their 
lack of perception of the consequences of diabetes, forgetfulness regarding taking medication, 
adverse effects of the prescribed medicines, living in rural areas, affordability and issues of motivation 
including family support (83, 86, 119-122).  There are also concerns with the concomitant 
management of hypertension and hypercholesterolaemia along with controlling HbA1c in patients with 
T2DM in SSA (61, 83, 123). Other potential factors impacting on key issues such as adherence 
include concomitant co-morbidities including infectious diseases appreciably increasing the pill burden 
and regimen complexity (124). Treatments for HIV can themselves also lead to weight gain and 
obesity further complicating the management of T2DM patients with HIV (20, 125-128). A study 
undertaken in an HIV clinic in South Africa found the metabolic syndrome was seen in 20% of cases 
within one year after initiation of anti-retroviral treatment (ART) despite the young age of patients, 
presumably as a consequence of ART exposure (129). Similarly, diabetes increases the chances of 
patients getting TB nearly threefold (20). Consequently, T2DM patients with infectious disease co-
morbidities must be carefully managed. 
 
There have been a number of initiatives across SSA to improve identification, prevention and 
management of T2DM to reduce subsequent morbidity, mortality and costs. These include national 
strategies (6, 7, 130-135) as well as the development of contextualised guidelines combined with 
research to demonstrate the need for strategies to improve guideline adherence and to assess their 
impact in practice (5, 20, 118, 132). There have also been strategies to improve access and 
availability of medicines (74, 75, 136-138), as well as strategies to improve the monitoring and follow-
up of patients including advice on the doses of medicines prescribed (110, 139, 140). However, such 
activities are not universal across SAA. Alongside this, there have been initiatives in SSA surrounding 
patient education and empowerment, along with support mechanisms such as the Central Chronic 
Medicine Dispensing and Distribution (CCMDD) initiative in South Africa, to improve access to 
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treatment as well as adherence to suggested lifestyle changes and prescribed medicines (26, 74, 
104, 108, 109, 141-145). However, only a limited number of papers have been published assessing 
the impact of different initiatives in these patients (117, 143, 145). We are also seeing the rise in 
mobile technologies to improve care including adherence to medicines (146, 147), which will be one 
of the subjects for future research projects in SSA. Typically, multiple interventions are required to 
improve the care of patients with T2DM (117, 137). However, resources to expand such interventions 
to derive maximum benefits have to be balanced against ongoing needs in other high priority health 
conditions (37).  
 
Consequently, the principal objective of this paper is to document and debate ongoing challenges and 
activities to improve the care of patients with T2DM in Africa especially around issues of adherence to 
changing lifestyles and prescribed medicines. This includes appraising key issues associated with co-
morbidities with infectious diseases such as HIV and the resultant implications. There have been a 
number of systematic reviews looking at key issues surrounding the management of patients with 
diabetes in Africa including initiatives to strengthen healthcare systems (26, 35, 36, 45, 51, 99, 104, 
138, 144, 148-150). We are also aware of the recent NCD research conference for Africa to share 
evidence and identifying research priorities (151). However to date, there have only been a limited 
number of publications that have comprehensively focused on all aspects of care covering diagnosis, 
prevention, education, and treatment including access to appropriate medicines for patients with 
T2DM and subsequent adherence rates. There have also been only a limited number of publications 
assessing the influence and impact of different interventions to improve the care of patients with 
T2DM in SSA. In view of this, we sought to document ongoing activities across SSA to improve the 
care of patients with T2DM as well as contextualise any findings from a wide range of co-authors from 
across SSA and wider to provide future guidance. This does not included issues of counterfeit 
medicines as this is outside the scope of this paper (152, 153). 
 
We have specifically chosen T2DM as this accounts for up to 95% of patients with diabetes in SSA 
(41). In view of this, we believe our findings and subsequent implications should be of interest to key 
stakeholders across Africa and wider to help further improve the care of patients with T2DM building 
on current efforts. We will be monitoring these developments in the future. 
 
Our approach 
 
We did not perform a systematic review since there have been an appreciable number of recent 
publications, including systematic reviews, discussing ongoing research in this area and its 
implications including current prevalence rates, health system concerns, as well as possible policies 
and ways to improve future care (13, 20, 26, 27, 36, 45, 51, 104, 138, 144, 146, 148-150). In addition, 
a number of the references, especially regarding ongoing national activities, are typically only 
available on the Internet as some of these have only just been launched. It is too early to assess the 
influence and impact of such national activities on key patient parameters as well as suggested 
activities to address key elements in the care provided. As mentioned, there have only been a limited 
number of publications to date in this area and only a limited number of studies including Sapkota et 
al from LMICs (117, 143, 145). 
 
To address this knowledge and policy gap, we used senior level personnel from governments and 
their advisers, clinicians, academia, rational medicine use advisers, HTA personnel, as well as patient 
organisation personnel, to suggest future activities for all key stakeholder groups across SSA to 
improve the future care of patients with T2DM. This included both short- and long-term initiatives, with 
the advice given based on relevant publications known to the co-authors coupled with their 
considerable knowledge of ongoing activities in their own countries. This builds on policy gaps and 
other recent papers to help improve the care of patients with T2DM across SSA (20, 26, 35, 150). The 
co-authors came from a wide range of backgrounds and countries in terms of their geography, 
population size, GDP per capita as well as progress towards universal healthcare. We have 
successfully used this approach before to stimulate debate in other priority healthcare areas and 
situations to provide future guidance (154-164). 
 
We did not split the African countries into low- or middle-income countries as the burden of T2DM and 
its implications is growing across all of Africa. Consequently, countries can learn from each other.  We 
also did not systematically review each paper for its quality using well-known scales such as the 
Newcastle-Ottawa scale or the Cochrane risk of bias tool as our emphasis was on contextualizing the 
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findings rather than performing a systematic review for the reasons given (99, 165-168). In addition, 
we did not review each paper to assess whether the presence of diabetes, especially T2DM, had 
been defined according to WHO and other internationally recognised diagnostic criteria in view of the 
objectives of this paper (26, 169).   
 
3. Ongoing activities and the implications 
 
Ongoing initiatives and activities among SSA countries to improve the identification and management 
of patients with T2DM will be described first before debating potential approaches among all key 
stakeholder groups to improve future identification and management of patients with T2DM in SSA. 
This includes the cascade of treating patients with T2DM starting with glucose testing, diagnosis, 
lifestyle advice as well as the prescribing of medicines and counselling for adherence to prescribed 
medicines (26). We are aware for instance that most guidelines on the management of patients with 
T2DM in LMICs including SSA are inadequate in terms of their applicability, clarity, and active plans 
for dissemination (150). We are also aware that national guidelines when produced are not always 
readily available in primary and community healthcare centres or routinely consulted (170, 171).   
 
As mentioned, there will be a particular focus on strategies to improve access to medicines and 
subsequent adherence rates to prescribed medicines based on the combined experiences of the co-
authors and the published literature. 
 
3.1 Ongoing initiatives and activities among sub-Saharan African countries 
 
Table 1 contains details of a range of activities being undertaken among SSA countries to improve the 
management of patients with T2DM. 
 
Insert Table 1 
 
3.2 Suggested activities among all key stakeholder groups to improve future management of 
patients with T2DM 
 
We have based  suggested activities and initiatives that still need to be undertaken among key 
stakeholder groups across SSA to improve the cascade of patient management (26), and 
subsequently reduce future morbidity, mortality and costs due to T2DM and its complications, 
principally on the experiences of the co-authors in the absence of published data. These are 
contained in Boxes 1 to 5 and build on Table 1.  
 
Suggested activities include increasing recognition of the burden of T2DM across SSA to raise its 
priority status. As a result, seek to appreciably reduce the number of patients across SSA currently 
not being diagnosed with T2DM including those with pre-diabetes. Concerns with the availability and 
use of medicines, especially those contained in the WHO EML,  needs to be addressed including 
metformin. There are also concerns with poor adherence rates to prescribed medicines and 
prescribing guidelines, the routine availability of prescribed medicines, and the development of insulin 
resistance among diabetic patients which also needs to be addressed to reduce future morbidity and 
mortality. The complexity of the management of patients with T2DM is enhanced in they have 
infectious diseases such as HIV and TB, which is appreciably more likely in SSA than high income 
countries where most guidelines emanate from. As a result, guidelines need be country and region 
specific taking into account genetic and other factors including patients with diabetes in SSA having 
low to normal BMIs, those with ketosis-prone T2DM, as well as appropriate management of those 
with co-morbidities including hypertension and infectious diseases. This is unlike the situation in many 
other continents.    
 
Suggested activities will include those at governmental and national levels as well as among the 
different healthcare professional groups and patients to improve the future care of patients with 
T2DM. Potential initiatives to improve adherence rates to prescribed medicines will also be discussed 
given current concerns. 
 
In addition, there is an ongoing need to improve HTA capabilities across SSA to help fully assess the 
effectiveness and cost-effectiveness of different approaches, including different treatment approaches 
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especially given limited available resources, and potentially multiple possible initiatives. This can build 
on existing research across countries (151, 172-176) for evidence based decision making.  
 
4. Discussion and conclusion 
 
We believe this is the first comprehensive study to collate ongoing and planned activities across 
Africa to improve the management of patients with T2DM as well as suggest potential future 
strategies especially around medicine management. As a result, enable SSA countries to compare 
and contrast ongoing activities as well as debate potential future activities whilst the evidence base 
grows regarding their potential influence on reducing future morbidity, mortality and costs due to 
T2DM.  
 
It is encouraging to see that an appreciable number of African countries are actively instigating 
programmes to improve the care of patients with T2DM starting with improving diagnosis (Table 1), 
with countries such as Cameroon looking to instigate pilot activities starting in key regions. This is 
important with T2DM a growing problem across Africa with an estimated 15.9 million adults in Africa 
currently with diabetes and growing (19, 20), and recognises the growing burden of NCDs across 
Africa, and we will be reporting on some of the findings in the future. 
 
Key national activities in Africa (Box 1) include health system strengthening as well as improving the 
subsequent management of patients with T2DM including those with co-morbidities. This starts with 
the development or refinement of national action plans to enhance the care of patients with NCDs 
including those with T2DM. Initial activities include improved screening and diagnosis of high risk 
patients at a number of venues including schools, workplaces, churches and shopping centres as well 
as in PHCs. This includes patients with pre-diabetes especially those with other cardiovascular 
diseases (14, 15, 177) to reduce future morbidity, mortality and costs. Treatment approaches 
comprise both pharmacological treatments to prevent cardiovascular complications as well as lifestyle 
changes including diet changes.  
 
Access to medicines is especially important in SSA with for instance up to 75% of patients having 
difficulties with obtaining insulin (26). The very least is routine availability of metformin, appropriate 
SUs and soluble and intermediate insulins. The development of universal health care as well as the 
assistance of donors and commercial organisations can be beneficial here (74, 75, 136). Initiatives to 
encourage the use of generics where possible, obtain low prices for quality medicines, as well as 
instigate effective distribution systems can also enhance access to effective medicines in both public 
and community health centres (20, 74, 178, 179). The development and instigation of evidence based 
guidelines taking account of local co-morbidities including HIV and TB as well as genetics will also be 
a key step towards improving the management of patients with T2DM across Africa, enhanced by the 
auditing of current prescribing patterns (20, 150). Furthermore, key stakeholder involvement in the 
production of country guidelines is seen as important to enhance their utilisation building on the 
experiences in other countries (180-182).  
 
A key concern in SSA is the multi-morbidity among patients with T2DM including co-morbidity with 
HIV and TB. This adds to the burden of the disease, exacerbated by these infectious conditions. 
Consequently, country specific guidelines need to be cognisant of this with rapid referral systems in 
place for more complex cases given the improved management of patients in tertiary centres. 
Prescribers need to be cognisance of the potential for HIV treatments to exacerbate diabetes and also 
for diabetes to exacerbate TB. This needs to be emphasized during physician and healthcare 
professional training, followed up by continuous professional development and other activities.  
 
Concerns with the pharmacological management of patients with T2DM include adherence to 
medicines, which is typically sub-standard, as well as insulin resistance. A number of studies have 
shown the importance of healthcare professionals such as pharmacists, nurse practitioners, and 
community health workers, improving subsequent adherence and outcomes (95, 99), with more 
studies planned given current concerns. We envisage that innovative approaches such as the 
increasing use of mobile technologies will be adopted to enhance adherence to lifestyle changes and 
medicines, and we will be monitoring this development in the future (147, 183). Countries can also 
continue to learn from each other to improve future care. 
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Whatever new initiatives or treatment approaches are chosen, it is likely that countries will need to 
expand on their health technology assessment (HTA) capabilities to assist with rational choices given 
continuing pressure on resources. This is already happening in countries such as Ghana and South 
Africa, and will expand further. Potential choices for governments consist of enhancing the 
infrastructure including public/ community healthcare centres with multiple personnel including 
physicians, medical officers, pharmacists, nurses, and others, to aid identification and reduce the 
development of complications and associated hospitalisation. In addition, seek ways to address key 
issues regarding the availability of medicines for the management of diabetes and its complications 
including reducing co-payments where these exist. Multiple approaches also appear needed to 
address poor adherence rates to prescribed medicines where these occur, and these will be the 
subject of future research projects. 
 
In conclusion, we believe our findings and subsequent implications, including suggested activities 
(Boxes 1 to 5) for all key stakeholder groups, should be of interest to key groups across Africa and 
wider benefit the continuous improvement in the care of patients with T2DM in sub-Saharan Africa 
building on current efforts (Table 1). This is essential given rising rates of obesity in Africa with their 
subsequent impact on morbidity, mortality and costs. We will be monitoring these developments in the 
future especially as more studies become available evaluating ongoing initiatives among the different 
African countries and the implications.  
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Tables and Boxes 
 
Table 1 – Synopsis of ongoing national and local activities to improve the management of patients 
with T2DM in sub-Saharan Africa 
 
Country Activities 
Botswana • As part of Botswana National Multisectoral Strategy for the Prevention and 
Control of Non-Communicable Diseases 2017-2022 a number of activities are 
in place including (184): 
o Disseminating information on NCD prevention including T2DM 
regularly in various media outlets 
o Training and deploying community health agents (e.g. health 
education assistants) to conduct community outreach awareness and 
screening activities 
o All schools to integrate NCD education in health promotion curriculum 
o Promoting access to healthy food, including at schools (taxation on 
imports of unhealthy foods, regulations on food provided at schools or 
packed from home in both private and public schools) 
o Promoting physical activity at the workplace, at schools and 
recreationally 
• The Diabetes Association of Botswana collaborates with various 
organization/companies to conduct staff wellness activities; with services 
including screening for diabetes and education on physical activity, healthy 
eating among others (185) 
• Establishment of Diabetes clinics in different parts of the country as well as 
regular training of healthcare staff on diabetes management. Through the 
NCD unit at the Ministry of Health, education sessions on diabetes 
management using the primary health care guidelines - Hypertension and 
Diabetes (186) 
• Annual screening for diabetes mellitus across the country on World Diabetes 
Commemoration day 
• Training of community health care professionals who are already involved in 
HIV care on diabetes management and education given the complexities 
involved including increased weight gain with treatments for HIV 
• Increasing instigation of quality of care audits at different time intervals 
Cameroon • There are currently no ongoing national and local activities to improve the 
management of patients with T2DM in Cameroon 
• However, there are ongoing initiatives entitled “Cameroon National Diabetes 
and Hypertension Programme” - WDF16-1429 led by Prof Jean Claude 
Mbanya which aims at improving diagnosis and management as well as the 
prevention of diabetes and its complications in 2 regions of the country (North 
West and Centre) (187) 
• The key components of the programme include:  
o building capacity to improve diabetes and hypertension care both at 
the national and district level 
o strengthening the administrative and monitoring capability of the 
Cameroon Ministry of Health 
o improving the surveillance systems for NCDs in the country  
o implement campaigns among the population to raise awareness at 
the community level and among the media 
• The outcomes of any initiatives will be reported in the future 
Ghana • A Non-communicable Diseases Control Programme (NCDCP) was 
established by the Ministry of Health of Ghana in 1992 to respond to the 
growing burden of NCDs coordinating the national response to NCDs, 
working in partnership with other departments within the health sector, other 
Ministries, NGOs and civil society organizations (188) 
• In 1993, the NCDCP described general strategies for the prevention and 
control of chronic NCDs as well as disease-specific strategies, proposing a 
two-phase implementation of the programme, from January 1994 to 
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December 1998 and from January 1999 to December 2004, with specified 
targets for each phase (188, 189).  In 1994, the MoH identified the 
development of more effective and efficient systems for the surveillance, 
prevention and control of non-communicable diseases as one of the main 
strategies to achieve its health service targets by the year 2008 (188) 
• In 1998, another strategy paper was prepared with the view to document the 
burden of the problem, identify the risk factors and design the most 
appropriate intervention packages relevant to the Ghanaian situation (188). In 
2006-2007, strategic frameworks for the control of the major NCDs were 
developed with increasing levels of obesity and CV diseases in the Ghanaian 
population (4, 188) 
• In June 2012, the Ministry of Health in Ghana launched its National Policy for 
the Prevention and Control of NCDs spanning 2012 to 2018 spanning issues 
of primary prevention and health system strengthening (131). Whilst the 
National Health Insurance Scheme (NHIS) in Ghana does not reimburse 
healthcare facilities for secondary prevention in terms of routine screening 
services for patients with T2DM, NHIS covers tertiary care of DM patients in 
terms of their management. The facilities provide services including inpatient 
and outpatient services together with oral hypoglycaemic drugs and insulins. 
All regional hospitals in the 10 administrative regions in Ghana and some 
selected district hospitals providing primary care have specialized DM clinics 
providing comprehensive care. These are either open for access in the entire 
week or have selected consulting days in the week 
• More recently: 
o There is also a new requirement by the Ghana Medical and Dental 
Council for doctors to accumulate credit points for re-licencing every 
year including update information on the treatment of NCDs 
o There is also a current initiative to improve on the clinical skills of 
pharmacist through the provision of the doctor of pharmacy (PharmD) 
programme in all public universities as a first degree in pharmacy and 
also specialist pharmacist training at the both Ghana College of 
Pharmacist and West African postgraduate College of Pharmacist to 
improve on the quality of pharmaceutical care provided by pharmacist 
in both community and hospital pharmacies including patients with 
NCDs such as T2DM 
Lesotho • A number of activities are ongoing including (190): 
o Operational policies and strategic action plans for patients with 
diabetes including addressing key issues such as physical inactivity 
o Ongoing developments surrounding guidelines and protocols of care 
for patients with diabetes 
o Strategies to enhance the referral of patients from primary care to 
more specialised services when pertinent to help reduce future 
complications 
Kenya • There are a number of strategies ongoing in Kenya to improve the 
management of patients with T2DM. These include: 
• Implementation of the Non-Communicable Disease 2015-2020 (191), 
which includes raising the priority of NCDs such as T2DM, promoting 
healthy lifestyles, promoting and conducting research to reduce NCDs as 
well as strengthen monitoring and evaluation systems. This builds on the 
Kenya National Diabetes Strategy 2010-2015 (130)  
• Incorporation of diabetes education into the National Health Policy 
enhanced by the provision of Educator Manuals (192) as well as 
education to patients and healthcare providers by Diabetes Kenya whose 
mission is to provide a high standard of diabetes education and care as 
well as implementing prevention programmes (193). Diabetes Kenya also 
links people with diabetes to resources and supply centres at discounted 
rates as well as publishing a quarterly journal, booklets on Diabetes care 
and Diabetes Brochures to help improve the care of patients with diabetes 
in Kenya  
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• Promotion of diabetes self management supported by regular clinical 
follow-ups and the incorporation of diabetes screening in all medical camp 
activities particularly those targeting rural hard to reach areas 
• Joint collaboration between Familia Nawiri, a social venture program 
initiated in Kenya by Novartis, and several County Ministries of Health in 
partnership with the Centre for Research in Therapeutic Sciences at 
Strathmore University, Kenya, and the Swiss Tropical and Public Health 
Institute, Switzerland, to strengthen the government’s community health 
strategy through training of community health workers and health 
promotion at the household level (194) 
• Enhanced health cover for outpatient and inpatient care through the 
expanded National Hospital Insurance Fund with most patients with 
diabetes in Kenya certainly in the rural setting diagnosed in public 
facilities (194), although others have found that most patients are 
diagnosed in hospitals or private facilities rather than public clinics or 
health centres where there is a greater supply of pertinent medicines (62) 
• Improving access to care including medicines (75, 136) and improving the 
supply chain, with metformin and glibenclamide, the most prescribed 
medicines for patients with diabetes in Kenya (194). In addition, 
enhancing access and availability of medicines through Universal Health 
Coverage (UHC). Currently, there is typically low availability of medicines 
in the public sector. As a result, most patients currently purchase their 
privately from community pharmacies and clinics largely out of pocket 
even though they are available free-of-charge in public clinics (62, 195, 
196) 
• Enhancing capacity building through targeted specialist training in 
diabetology 
• Sanofi in partnership with the International Diabetes Federation (IDF), Kenya 
Diabetes Study Group and Diabetes Kenya, supported by the Ministry of 
Health, launched mid 2019 a nationwide on-line three-month diabetes 
management training programme initially targeting 2000 General 
Practitioners. The objective being to help bridge the gap in the management 
of diabetes in Kenya with only a small number of diabetes specialists (12) 
currently available (197) 
• Boehringer Ingelheim with PharmAccess has also recently launched a mobile 
technology enabled program, “Tiba Yako” for Hypertension and Diabetes 
Patients  to empower patients to become more aware, access care and take 
charge of their diabetes via a mobile health wallet, M-TIBA, and enables 
patients to manage their diabetes from their own home through digital tools 
(198) 
• The Digital Diabetes Patient Support Program (PSP) was also recently 
launched in Nairobi, Kenya, by Sanofi Kenya in partnership with CheckUps 
Medical Center in 2019. The program branded SPEED (Sanofi Patient 
Enlightenment and Empowerment Drive) looks to promote safe and effective 
use of medicines especially for patients with T2DM with up to 45% of adult 
diabetic patients or more currently not adhering to their oral diabetic 
medication (199) 
Kingdom of 
Eswatini 
(formerly 
Swaziland) 
• There are ongoing initiatives in the Kingdom of Eswatini to increase 
awareness of T2DM especially among women including the necessity to 
adopt changes in lifestyle (200), with diabetes accounting for 24% of deaths in 
patients with NCDs admitted to hospital (7), an increase on previous years 
• These include the development of essential healthcare packages including 
patients with chronic diseases (201) 
• The National Prevention and Control of NCD 2017 report highlighted a 
number of activities to help reduce morbidity and mortality of patients with 
diabetes (7). These included:  
o The development of the Educational Health Care Plan which states that 
screening for identification as well as for management of diabetes should 
be offered at all levels of care. Selected screening tests such as blood 
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sugar levels as well as fundoscopy and some specialized treatments 
such as nutritional supplements should be offered at all levels with 
currently only 35% of centres offering screening services 
o Restructuring and upgrading of services including enough human 
resource to enable decentralisation of services from national to regional 
and local centres 
o Undertaking research to more accurately assess current incidence and 
prevalence rates to align services to improve future care 
Namibia • National Policy Framework for diabetes prevention and control in 
Namibia. Key areas include: 
o Establishment of the National NCD Programme in the Ministry of 
Health and Social Services under the mandate of office of the Prime 
Minister    
o Government commitment to funding public health care including 
diabetes 
o Regular updates and reviews of STGs and essential medicines lists 
incorporating diabetes care 
o Publication of the national multi-sectoral strategic plan for prevention 
and control of non-communicable diseases (NCDs) in Namibia 
2017/18 – 2021/22 (202)  
o Nutrition guidelines for prevention and management of non-
communicable diet related diseases (203) 
• Universal Health Coverage for diabetes – key aspects include: 
o Provision of diabetic care as close to the family as possible at nearly 
no cost in the public sector and ensuring cost-effective access to care 
through various medical aid schemes since there are concerns with 
issues such as attendance in primary care clinics and adherence to 
medicines if facilities are not close to families (94) 
o Establishment of specialist-run Diabetes Clinics in referral hospitals 
o Integration of diabetes care as part of primary health care delivery 
including regular screening in the communities and improved access 
to diabetes testing at the community healthcare level 
o National laboratory service through the Namibia Institute of Pathology 
to provide cost-effective testing for diabetes 
• Special Interest and Advocacy Groups on diabetes 
o Commemoration of Healthy Lifestyles Day aimed at raising public 
awareness on the prevention of NCDs including diabetes 
o Community advocacy and awareness on diabetes by several interest 
groups such as the Diabetes Association of Namibia, University of 
Namibia Diabetes Association and Namibia Diabetes Lifestyle 
Foundation (204, 205) 
o Collaborative operational and clinical research on diabetes 
prevention, treatment and control 
• National Surveillance of Non-communicable and communicable 
diseases: 
o Undertaking Namibia demographic health surveys (NDHS) to 
ascertain the current prevalence of diabetes and prediabetes as a 
basis for developing future programmes to reduce prevalence rates 
especially T2DM (206) 
• Building sustainable capacity in the care and control of diabetes 
especially T2DM 
o Incorporating NCDs as part of training curricula of pre-service and in-
service health professions training programmes including Medicine, 
Pharmacy, and Nursing 
Nigeria • On-going joint efforts by The Diabetes Association of Nigeria and The Federal 
Ministry of Health to review the Guideline for the management of Diabetes 
Mellitus in Nigeria aimed at addressing current challenges as the last edition 
of the guideline was published in 2011 
• Efforts to strengthen the care of patients with diabetes at the PHC level 
through development of guidelines, training of medical officers, nurses, 
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pharmacists and community health workers at the PHC level and 
establishment of diabetes mellitus registries at the local government levels 
• Pilot scheme in Lagos State, Nigeria, being sponsored by the State 
Government and Health Matters Inc. to improve diabetes care in poor urban 
communities in Lagos City among 35 PHCs located in hard-to-reach slum 
areas. The project will seek to increase awareness about diabetes through 
awareness and screening camps via radio campaigns (207) 
• Awareness and Advocacy programs organised nationally and locally by 
various interest groups and societies such as Diabetes Association of Nigeria 
(DAN) and The Endocrine and Metabolic Society of Nigeria (EMSON) 
especially during World Diabetes Days with educational materials produced 
and distributed. 
• Creation and regular meetings of Patient Support Groups by The Diabetes 
Association of Nigeria (208) 
• Periodic free health screening programs at community levels to identify 
undiagnosed cases of T2DM 
South Africa • Various initiatives are ongoing to improve the care of patients with T2DM 
throughout South Africa These include the following: 
o Publication of updated South African guidelines for the management 
of patients with T2DM (5) 
o Recent instigation of a tax on sugar (2018) (209) 
o Increasing patients’ empowerment of their T2DM through counselling 
and patient diaries via pharmacists and others, i.e. improve diabetes 
self-management (5, 145) 
o Instigation of free screening centres for patients with suspected 
diabetes  
o Follow up of patients with diabetes and those at high risk in the public 
sector by outreach healthcare workers in rural areas (140) 
o Potential instigation of ward-based outreach teams (WBOTs) to 
improve access to primary healthcare (PHC) services including health 
promotion and disease prevention for patients with T2DM (210) 
o However, it is recognised that the management of patients with T2DM 
in the public sector is under-resourced. This may change with the 
introduction of a National Health Insurance Bill for Universal Health 
Coverage which will facilitate and promote the provision of health 
services for the management, prevention and control of 
communicable and NCDs (211) 
• Ongoing initiatives by the Government to realise its vision of a country free 
from the burden of disease include a multi-sectoral national wellness 
campaign “Cheka Impilo”, which is a call to action for South Africans to move 
from a curative response to health to preventative approaches and the 
adoption of healthy lifestyles. The campaign was launched on 
commemoration of World AIDS Day, on 1 December 2018, and provides 
national support for testing and treating people who have HIV, TB, sexually 
transmitted infections and NCDs such as diabetes and hypertension,  
reinforcing the implementation of prevention strategies, linkages to care, 
management, treatment and support (212)  
• National Adherence Guidelines for Chronic Diseases (HIV, TB and NCDs) 
launched in 2016 for phased implementation throughout the country. This 
includes standard operating procedures for the early implementation of 
interventions in a sequential manner to support linkage, adherence and 
retention in care (134, 135). Evaluation of the impact of five of these 
interventions is currently being undertaken in a sample of PHCs in four of the 
provinces in South Africa (213) 
• Implementation of the Centralised Chronic Medication Dispensing and 
Distribution (CCMDD) programme, to improve access to chronic medication 
for stable patients through pre-dispensing and delivery to a point closest to 
the patient (74). The programme comprises two components: Central Chronic 
Medicines Dispensing and Distribution (CCMDD) and Pick-up Points (PuPs). 
With these initiatives, PHCs are decongested and patients will no longer be 
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required to travel long distances and wait several hours to collect their 
medication at healthcare facilities 
• Synchronised National Communication in Health (SyNCH), which is a web 
system designed to improve process flows and transparency of the CCMDD 
programme. This is a first for the South African public healthcare system, 
providing local, real-time data that informs decision-making and guideline 
development. Perceived advantages of the system include ensuring 
compliance to STGs, reducing medication errors and prescription rejections 
through validations built into the system, monitoring medicine collection status 
and promoting the rational prescribing of essential medicines. In terms of 
patient care, SyNCH facilitates patient adherence to treatment through the 
PuP interface and automatic notifications to healthcare facility for follow-up, 
thereby reducing the time taken to identify non-adherent patients 
• HIV Testing Service currently incudes screening for HIV, TB, diabetes, 
hypertension, obesity and cervical cancer, with this service being used for 
screening multi-morbid conditions 
• Gauteng Province has been implementing a policy for health, happiness and 
wellness of its residents through though a comprehensive health prevention 
and promotion programme.  
• Cities changing Diabetes project currently being implemented Johannesburg 
included establishing a health service laboratory in a PHC clinic where smart 
protocols, smart technologies (such as point of care machines), smart 
medicines including insulin analogues where appropriate are being used 
under the leadership of a multi-disciplinary team comprising specialists in 
internal medicine, public health medicine, social workers, pharmacists, 
nursing staffs, allied health care workers and community health care workers  
• The South African Diabetes Association also provides educational and other 
support services; however variably influence on policies compared with other 
countries 
• Of current concern is that the South African Nursing Council does not 
recognise the role and qualification of Diabetes Nurse Educators. However, 
there are ongoing moves to have this qualification officially recognised to help 
improve patient care in the future 
• In the private sector, diabetes is typically managed in conjunction with 
Managed Care Programmes with variable effect. Medication formularies are 
in place to support care and reduce costs. In general, though, the Health 
Insurance companies seem more concerned with month-by-month costs of 
management rather than longer term outcomes 
• However, there are moves to upskill healthcare professionals in diabetes 
management and care in the private sector. This includes attendance at a 5-
day intensive, advanced course in diabetes care, offered by the Centre for 
Diabetes & Endocrinology (CDE) Academy. To date (July 2019) over 1700 
medical professionals, over 1000 nurses, over 450 dieticians as well as more 
than 300 other health care professionals have attended this particular course. 
This includes a number of participants from neighbouring SADAC countries 
• The CDE also promotes further training and education of healthcare 
professionals in diabetes management and care, such as an online 
Postgraduate Diploma in Diabetes and MSc Diabetes offered by the 
University of South Wales. To date (July 2019) 168 successful Postgraduate 
Diabetes Diplomas and 49 MSc’s in Diabetes have graduated 
• In addition to the above formal qualifications, there is an initial 10-week online 
foundation course in diabetes offered by the University of South Wales, and 
promoted by the CDE in South Africa 
Sudan • Ambulatory centres working as multidisciplinary institutions specializing in 
diabetes care were recently established in Sudan with funding from The 
World Diabetes Foundation. The aims are (214):  
o Provision of specialized medical care for diabetic patients 
o Raising the public awareness about diabetes mellitus and its 
complications 
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o Enhance specialized training of medical and paramedical staff 
working in diabetes management. 
• Establishing the Diabetes Care Organization, which is one of the voluntary 
non-profit organizations under the Sudan Diabetes Federation with the aim of 
leading the provision of Diabetic Health Care services to communities across 
Sudan 
Zambia • Zambia has recently introduced a national health insurance scheme aimed at 
improving and addressing access to healthcare and financing gaps, especially 
for patients with NCDs in Zambia. This is important since whilst Zambia has 
national policies and treatment guidelines for DM, operational policies and 
action plans are still required to reduce the risk of T2DM including public 
health promotion and educational prevention strategies in primary healthcare 
especially for high risk groups e.g. older age, overweight and obese (128) 
• The future care of patients with T2DM should be helped by the introduction of 
healthy lifestyle campaigns (led by and exemplified by the Country President) 
to promote regular exercise as preventive measure among the citizens of 
Zambia. The Diabetes Association of Zambia is helping here 
• However, Zambia currently lacks a national diabetes registry affecting health 
system planning and decision-making 
Zimbabwe • Zimbabwe adopted the primary health care approach according the Alma Ata 
Declaration. There is currently a structure in place within the Ministry of Health 
handling NCDs headed by a deputy director. The office of the deputy director 
reports to the director of epidemiology who subsequently reports to the 
director of preventive services 
• There are two main organisations in Zimbabwe very active in issues related to 
patients with T2DM. The Zimbabwe Diabetic Association( ZDA) consists of 
patients with diabetes with a mission to improve the physical and socio-
economic welfare of patients with diabetes in Zimbabwe through regular 
promotion and other activities (215). Alongside this, there is the recently 
formed Zimbabwe Endocrinology, Diabetes and Metabolism Association 
(ZEDMA) in April 2018  
• The Ministry of Health in Zimbabwe in 2019 plans to conduct an NCDs risk 
survey with WHO support, with the last survey (STEPS) conducted 2005 
giving a prevalence of T2DM at 10.2% as the MoH acknowledges that NCDs 
have been largely neglected in preference to HIV and TB 
• Training workshops on essential NCDs package including T2DM will be 
conducted starting in August 2019 and the Essential Drug List of Zimbabwe 
(EDLIZ), including the management of Metabolic and Endocrine conditions, 
will also be published in 2019 version (last updated in 2015). Zimbabwe 
guidelines for diabetes management are currently largely contained in the 
EDLIZ  
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Box 1 – Suggested activities among national governments and authorities 
 
A) Short term 
• Prioritise the screening for diabetes at all health care facilities in the country including those 
with diabetes alongside infectious diseases such as TB (216). This includes providing the basic 
tools and technologies to identify at risk patients and to monitor their progress - including 
providing BP monitors in all clinics alongside glucose monitoring systems, with the provision of 
self-monitoring systems important for patients on insulin 
• Improve the routine availability of medicines in the public sector to treat patients with T2DM 
including addressing concerns with the current lack of metformin, SUs or insulins when this 
occurs. This includes ensuring the availability and use of low cost quality medicines (generics) 
to reduce patient co-payments where applicable. Initiatives could include improved supply 
chain management incorporating better stock control and forecasting abilities - building on 
initiatives in South Africa such as the Central Chronic Medication Dispensing and Distribution 
(CCMDD) (74) – as well as improved regulatory controls limiting the availability of poor quality 
generics where this is a concern 
• Introduce or enhance the implementation of programmes including educational programmes 
among T2DM patients to improve their lifestyles in association with other groups such as 
patient associations and other relevant NGOs 
• Review and improve where pertinent the training of healthcare professionals in the 
management of patients with T2DM in both undergraduate and postgraduate programmes to 
improve future quality of care. This can include instigating CPD activities, and builds on 
ongoing programmes in Ghana, South Africa and wider 
• Instigate/ refine training programmes at both undergraduate and postgraduate levels to 
improve the care of patients with T2DM. This can include developing and implementing CPD 
programmes building on initiatives in Ghana to upskill their knowledge – including 
understanding of the different oral medicines to treat T2DM and insulin preparations as well as 
their role and place especially in patients with various co-morbidities 
• Instigate policies to enhance adherence to prescribed medicines and dietary modifications 
building on ongoing initiatives across SSA including Kenya and South Africa as well as 
learnings from other NCDs. This involves improved understanding of key factors influencing 
adherence including the level of education, family and support systems and funding issues, 
which is critical to enhance the future care of T2DM patients. It is likely mobile technologies will 
play an increasing role  
• Instigate training and other measures to improve the detection and treatment of T2DM-related 
causes of blindness such as diabetic retinopathy as well as causes of renal complications 
including preventative measures along with general measures to improve BP control (217, 218) 
•  
B) Longer term 
• Leadership and governance 
• Greater prioritisation of NCDs especially T2DM with its implications for morbidity, mortality and 
costs. As part of this, instigate activities to develop or refine national strategies to improve the 
care of patients with T2DM, building on current activities among SSA countries (Table 1). This 
can include implementing national NCD strategies with their emphasis on identification, healthy 
lifestyle changes (physical activity, healthy eating, limiting process foods and weight 
management – including addressing concerns with any stigma/ negative perceptions 
associated with weight loss) along with adequate treatment of patients with T2DM based on 
agreed national guidelines (cognisant of local co-morbidities including infectious diseases 
among the different SSA countries)  
• Conduct screening for NCDs including T2DM among at risk individuals including those with a 
family history of diabetes, overweight or obese at schools, workplaces, churches and shopping 
centres as well as in PHCs 
• Health workforce 
• Strengthen health care systems including ambulatory care systems as well as policies and 
initiatives to better identify and manage patients with T2DM. This can include making better use 
of healthcare professionals and community health workers in primary/ community health clinics 
as well as community pharmacists to help with education and medication adherence (Boxes 3 
and 4)  
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• Seek to address shortages of physicians where applicable including training and utilising of 
other healthcare professionals such as clinical associates (or clinical officers), nurses and 
community pharmacists to help manage patients with T2DM. This can also include instigating 
home visits by healthcare professionals such as dieticians, diabetic nurse educators and 
podiatrists, to improve the care of patients; however, instilling that complex cases must be 
rapidly referred to specialists 
• Task-shifting through utilization of mid-level workers (such as pharmacist, physiotherapy, 
podiatry) to support the clinical management of NCDs. As a result, enhance the 
multidisciplinary approach to the management of patients with T2DM throughout the healthcare 
system 
• Undertake multidisciplinary research at local, regional and national settings to improve future 
care of patents with T2DM including adherence to medicines, and seek to instigate the finding 
• Financing 
• Accelerate the introduction of universal healthcare in the public sector where patient co-
payments are currently an issue to improve the care of patients with T2DM 
• Improved efficiency 
• Strengthen HTA capabilities especially when Ministries of Health are confronted with a number 
of potential initiatives coupled with limited resources, building on ongoing initiatives across sub-
Saharan Africa including Ghana, Kenya and South Africa (172, 174, 176, 219) 
• Address the social and cultural determinants of health in patients with T2DM through 
leadership at a national level if not already underway - building on initiatives in Botswana, 
Ghana, Kenya, Kingdom of Eswatini, Namibia and South Africa to prevent or manage the risk 
factors associated with T2DM  through greater stakeholder collaboration (6, 7, 87, 184, 191, 
220) 
• Disseminate NCD information including T2DM regularly in national political forums, e.g. public 
speeches and in parliamentary debates 
• Strengthen the monitoring and evaluation of the management and treatment of T2DM to ensure 
that efforts are in line with the burden of NCDs. This includes regular auditing of the 
management of patients with T2DM against agreed national guidelines and seek to introduce 
quality indicators where concerns. Quality indicators can include HbA1c, BP and lipid level 
goals developed with the help of all key stakeholders using robust methodologies (160, 221) 
• Research 
• Continue to research methods to improve medication and dietary adherence including 
counselling, concerns with process foods, addressing patients’ fears and beliefs including 
concerns with weight loss, potentially patient diaries and mobile messaging services, as well as 
measures to enhance patient satisfaction with healthcare services (40, 120, 145, 146, 222). 
Subsequently, seek to instigate such findings 
• Fund ongoing research around diabetic phenotypes among the African population compared 
with other continents and its impact on key issues such as insulin resistance to improve future 
care (18, 20) 
 
Box 2 – Suggested activities among physicians (hospital and ambulatory care) 
 
A) Short term 
• Instigate/ refine training programmes at both undergraduate and postgraduate levels to 
improve the care of patients with T2DM 
• This can include developing and implementing CPD programmes building on initiatives in 
Ghana as well as programmes to enhance timely diagnosis, management and follow-up of 
patients with T2DM including the management of patients with T2DM with HIV and TB 
• Instigate in-service training where pertinent including any updated guidelines for new medicines 
• Take part in Pharmaceutical (Drug) and Therapeutic Committees and other fora to ensure 
possible treatment decisions are in line with national guidelines and essential medicine lists, 
and evidence based especially where co-morbidities  
• Ensure prompt referral of patients (ambulatory/ primary care) to specialised centres where 
these exist and where necessary - including complex patients with multiple co-morbidities 
• Formulate care plans for patients and monitor prescribing (audit) against agreed guidance, 
especially those with co-morbidities including infectious diseases with rapid referral to specialist 
centres for more complex patients including those with multiple co-morbidities 
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• Communicate with patients the importance of adherence to medicines, and seek to monitor 
this. This can be through diaries and other mechanisms including the use of mobile 
technologies 
B) Longer term 
• Actively become involved in future research to improve the management of patients with T2DM 
in SSA given the high rate of co-morbidities especially infectious diseases in SSA compared 
with other continents as well as positive views towards overweight and obesity among 
populations in SSA 
 
Box 3 – Suggested activities among pharmacists (hospital and ambulatory care) 
 
A) Sort Term 
• Extend the role of pharmacists in hospitals and in the community to help improve the care of 
patients with T2DM. This can include counselling on issues of medication adherence, potential 
side-effects of medicines, and dispelling myths especially with community pharmacists often 
the first point of contact for patients with ailments in SSA 
• Encourage pharmacists to join national diabetes groups (such as ZEDMA in Zimbabwe) to help 
debate key issues regarding the use of medicines to treat patients with T2DM 
• Pharmacists as a vital part of the medicine supply chain need to instigate measures to reduce 
out-of-stock situations for essential medicines to treat patients with T2DM in public health 
facilities to reduce reliance on private pharmacies especially where co-payments are an issue 
• Pharmacists should also monitor medicine availability in hospitals as part of DTC activities to 
help reduce out-of-stock situations, and work with physicians and others to instigate alternative 
medicines should the need arise  
• Pharmacists should also seek to encourage the use of generic medicines where possible to 
reduce patient co-payments where pertinent 
B) Longer term 
• Pharmacists need to become actively involved with auditing medicine use and providing 
support and other services to improve medication adherence. These can include mobile alerts, 
diaries, storyboards and general information to enhance adherence, and can be part of DTC 
activities in hospitals as well as part of PHC activities in ambulatory care 
• Take part in research regarding factors impacting on medication adherence and possible ways 
to address this within their own health service, and seek to actively address and implement key 
findings 
 
Box 4 – Suggested activities among other healthcare professionals in ambulatory and hospital care 
including nurse practitioners 
 
A) Short term 
• Use nurse practitioners and others to help screen for T2DM in the community especially at risk 
groups (Box 1) 
• Work with other key stakeholders to provide accurate information to patients on the 
management of their condition including self-care to help prevent complications from occurring 
B) Longer term 
• Become involved with developing minimal standards of care for patients with T2DM in primary/ 
community healthcare centres and subsequently monitoring the management of patients 
against agreed standards. This can include lifestyle changes and adherence to medicines as 
well as identifying acute and chronic complications for rapid referral 
• Actively seek ways to provide support to patients and their caregivers to take control of their 
own health and to enhance adherence to lifestyle advice and any medicines prescribed 
• Actively seek to improve the knowledge of medicines and self-management practices among 
fellow nurses and other community health workers regarding the care of patients with T2DM to 
enhance task shifting efforts at primary/community level - ultimately helping to reduce time 
spent on long queues and the implications on key issues such as adherence. Concurrently with 
this, rapidly refer more complex patients to specialists given ongoing concerns  
• Provide evidence based care especially regarding complications of diabetes such as ulcers 
• Take part in research initiatives to improve the future care of patients with T2DM, and seek to 
instigate the outcome of any research activities 
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Box 5 – Suggested activities among patients/ support services 
 
A) Short term 
• Help communicate the importance of detection and management of T2DM including lifestyle 
changes and adherence to medicines to help reduce the morbidity and mortality of T2DM. This 
builds on progressive activities of a number of diabetes patient groups in SSA (Table 1) – and 
is especially important where there are limited facilities to manage the complications of 
diabetes including renal complications, retinopathy and diabetic ulceration 
• Help to instigate communication and other programmes to encourage patients to join national 
Diabetic Associations as well as generally encouraging patients and their carers to take part in 
peer education and support groups 
• Help provide easy to understand guidance to patients to help with their understanding of their 
condition as well as improve the management of their condition including lifestyle and 
medication advice. Such guidance should also help to dispel cultural and social stigmas 
associated with T2DM including those surrounding weight loss 
• Instigate activities encouraging recreational activities as well encouraging patients to ask 
questions when they are still unsure of their condition/ instructions given and to seek prompt 
medical help when they experience changes in their condition 
• Seek generally to strengthen family support structures through education and socio-economic 
empowerment 
• Work with all key stakeholders to enhance their understanding of any concerns that patients 
and their support network may have regarding the management of T2DM and potential 
complications to better target educational and other activities 
B) Longer term 
• Formulate and empower support groups among patients with T2DM such as adherence clubs 
to enhance the transfer of knowledge and self-management aspects among patients 
• Help longer term to develop innovative interventions tailored to the culture of patients in given 
SSA countries to enhance adherence to medication and lifestyle changes, such as storytelling, 
which have shown to be successful in other NCDs (223). This can increasingly be via mobile 
technologies and other support systems (30, 146, 183, 224) 
• Encourage greater involvement in the prevention of diabetes complications by self-monitoring 
of foot health and active participation in screening for eye, foot, and renal complications 
• Encourage key stakeholders to include patient support groups in future research activities and 
with the communication of their findings to improve future care   
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Appendix 
 
Appendix 1 - Prevalence rates of pre-diabetes and diabetes among a range of sub-Saharan African 
countries 
 
Country Prevalence rates 
Republic of 
Benin 
Prevalence rates including undiagnosed diabetes have been as high as 12.4% of 
the population although other authors have quoted considerably lower rates (20, 
225) 
Botswana Documented prevalence rates for diabetes range from 4.8% to 6% of adults, with 
prevalence rates rising with increasing rates of obesity in recent years (53, 226) 
Cameroon The prevalence of pre-diabetes is 7.1% (227), with the prevalence of diabetes in 
adults in urban areas currently estimated at 6 – 8% of the population (187) 
 
It is estimated that with as many as 80% of patients living with diabetes are 
currently undiagnosed (187) 
Democratic 
Republic of 
Congo (DRC) 
There are an estimated 1.8 million (1.5-2.2 million) people with diabetes in DRC 
(5) 
Ethiopia Up to 7% of the population have diabetes, with an appreciable number of patients 
unaware that they have this condition (11, 119) 
Ghana A recent meta analysis suggested the overall prevalence of diabetes among 
adults was high at 6.46% of the population (228), with previous studies also 
documenting high rates of diabetes in Ghana (131, 188) 
Kenya The prevalence of diabetes including T2DM in patients in Kenya has been 
estimated at 3.3% and rising up to 4.5% by 2025, leading to the development of 
national strategies to reduce associated morbidity, mortality and costs (22, 130), 
whilst others have reported lower and higher rates (17, 229) 
 
Having said this, Bastawrous et al (2018) estimated the cumulative incidence of 
DM at 61·0 per 1000 in people aged ≥50 years in Kenya (230), with recent 
increases exacerbated by changes in diet and inactivity (231) 
 
Published prevalence rates in Kenya are likely to be under-estimates considering 
the number of patients with undiagnosed diabetes and pre-diabetes (17) 
 
The International Diabetes Federation current estimates that there are 460,000 
people with diabetes in Kenya and likely to rise to 1.3 million within a generation 
unless addressed (197) 
Lesotho The prevalence of diabetes is 6% - 4.5% males and 7.5% females (190) 
Kingdom of 
Eswatini 
(formerly 
Swaziland) 
The prevalence of diabetes in the Kingdom of Eswatini is currently estimated at 
3.7% among the adult population, and predicted to rise substantially in the 
coming years unless key changes are made to the management of patients with 
diabetes in the country (232) 
 
Currently, patients with diabetes account for 9.5% of all outpatient visits in the 
Kingdom, with a greater prevalence among women (59%), and 17.4% of 
inpatients by admission (7) 
Namibia The prevalence of diabetes has been estimated at 5.1% and pre-diabetes at 6.8% 
(206) 
 
Ministry of Health figures suggest higher rates at 6% among women and 7% 
among men with 7% of women and 6% of men pre-diabetic (202), with rates 
higher in urban versus rural areas 
Nigeria The age-adjusted prevalence rates for T2DM among those aged between 20 and 
79 years has increased from 2.0% in 1990 to 5.7% in 2015, and rising (233), with 
others reporting prevalence rates as high as 10% of the population (142, 234) 
 
35 
 
A recent systematic review suggests an overall prevalence of 5.77%, highest in 
the south east (9.8%) and lowest in the north-east (3.8%) with urban dwelling, 
physical inactivity and unhealthy diets seen as are important risk factors (41, 235) 
 
However, it is estimated that up to 70 - 80% of patients with diabetes in Nigeria 
are either undiagnosed or untreated (21, 41), which is important since Nigeria 
currently accounts for one fifth of all the cases of diabetes in sub-Saharan Africa 
(41) 
 
Diabetes is also observed in up to a third of all admissions in medical wards 
adding to the burden (41). 
South Africa Published prevalence rates for diabetes vary between 7.2% to 10.1% or higher of 
the population depending whether undiagnosed patients are included (52, 128, 
140, 236, 237). Overall, it is estimated that 4 million South Africans currently have 
diabetes (1.2-4.6 million) (5, 151) 
 
However, based on the SANHANES data there is a higher prevalence of diabetes 
in South Africa (15.3%) should a high percentage of patients with diabetes 
actually be diagnosed and treated (52, 238) 
 
A recent report from Johannesburg found 66% obesity and overweight in a 
random population attending PHC clinics, with a 4.9% undiagnosed diabetes. All 
the cases, who were diagnosed are receiving care (100%) and of all the patients, 
who are receiving care, 31% of them were controlled. The prevalence of co-
morbidities including family history, obesity, overweight, hypercholesterolemia, 
hypertension, and HIV were common 
 
The analysis of HBA1C results from National Health Laboratory Service (2017) 
found 16% of 1.6 million patients from public health facilities in Gauteng Province 
had HBA1C <7% 
Sudan The current prevalence of diabetes in Sudan is estimated at 8%; however, this is 
not evenly distributed over the country. Prevalence rates are higher in some 
Northern states, and higher in urban (19.1%) versus rural area (2.6%) (239, 240). 
Individuals of Egyptian and mixed descent also have inreased risk of getting 
T2DM (241) 
 
Researchers attributed the increase in prevalence of diabetes in Sudan to the 
increase in obesity rates, increased sugar intake, lack of physical activity and 
excess carbohydrate intake (242-244), with approximately 40% of the cases of 
T2DM attributable to obesity among the population in Sudan 
Zambia Prevalence rates for diabetes are estimated at 3.5% up to 5.35% of the 
population (128, 132) 
Zimbabwe Pooled prevalence rates suggest 5.7% of the population have diabetes and rising 
(245) 
 
